期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Immunity LetPub Score 9.8
50 ratings
Rate
Reputation 10.0 Influence 9.8 Speed 9.1 | ||||||||||||||||||||||||
期刊簡稱 | IMMUNITY | ||||||||||||||||||||||||
ISSN | 1074-7613 | ||||||||||||||||||||||||
E-ISSN | 1097-4180 | ||||||||||||||||||||||||
h-index | 355 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 2.00%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | http://www.cell.com/immunity/home | ||||||||||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/IMMUNITY | ||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||
出版商 | Cell Press | ||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||||||
發行頻率 | 月刊 | ||||||||||||||||||||||||
創刊年 | 0 | ||||||||||||||||||||||||
每年文章數 | 165每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 73.29% | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1074-7613%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 6 Month(s) | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: About 50% | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Immunity] 的評論 | 撰寫評論 |
作者: 重阳睿文 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-06 20:48:07 評論於 How long does the first external audit usually take?(0) 讚! | 重阳睿文 |
作者: 本尼迪克特梦露 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-07 08:10:04 評論於 Review speed: 2.0 | Submission hit rate: 5.0 Research focus: tumors; infections; basic immunology experience sharing: Immunology research journals are roughly as follows: Tier 1 - Cell, Nature, Science Tier 2 - Cell sub-journal Immunity, which has been rapidly rising in recent years, with an impact factor surpassing Nature Immunology; Nature sub-journal Nature Immunology, which has seen a slight decrease in impact factor in recent years, but remains one of the best journals in the field of immunology; Nature sub-journal Nature Medicine, one of the best choices if there is a clear mechanistic study with potential clinical applications. In any case, the boss's submission preference is to submit to Immunity > Nature Immunology > Science Immunology, excluding CNS. Tier 3 - Journal of Experimental Medicine, a longstanding immunology journal, whose impact factor has been gradually declining, but the articles published therein are not to be taken lightly. However, in the past two years, they have also been accepting more research from other medical fields; Nature sub-journal Nature Cell Biology, which leans more towards classical cell biology, but occasionally features articles with an immunological focus; Journal of Clinical Investigation, a longstanding medical research journal, and Science's newer sub-journal Science Translational Medicine are also in this tier. Additionally, journals like Journal of Allergy and Clinical Immunology, Blood, and Gastroenterology are also very reputable(0) 讚! | 本尼迪克特梦露 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 23:53:29 評論於 SPSS (Statistical Product and Service Solutions), "Statistical Product and Service Solutions"(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 20:41:39 評論於 Mainly write about the use of animals, cell culture methods; main experimental operation methods; operation methods of techniques and instruments(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 八坂篷蔚 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 22:32:11 評論於 What is required in the general method?(0) 讚! | 八坂篷蔚 |
作者: 上清雨真 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 09:44:37 評論於 What statistical method is generally used?(0) 讚! | 上清雨真 |
作者: 日月小菊 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-06-29 09:16:52 評論於 22.5, exceeded NI(0) 讚! | 日月小菊 |
作者: 阿尔杰伯莎 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-05-18 22:16:45 評論於 Cell subjournal. Immunology experts. It's hard. But it feels like some groups have managed to publish a lot after getting the hang of it(0) 讚! | 阿尔杰伯莎 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-16 15:20:13 評論於 Who can predict how many points there will be next year?(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-12-26 22:07:38 評論於 Review Speed: 2.0 | Submission Hit Rate: 5.0 Sharing experience: The journal Immunity is more objective than the three major journals C N S, and values your work itself more. As long as your work is innovative enough and the data is relatively systematic, they will choose to send your article for review. The latter three journals value the weight of the author, and it is difficult to have a review opportunity if you do not have a heavyweight big name attached. My article took a month and a half for the first review in this journal (on the 32nd day, all reviewer comments returned to the editor, they will consider for 11 days, so the comments returned to me one and a half months later). After revising and resubmitting, the second review only waited for 14 days, all comments returned to the editor, and after 11 days of discussion, the comments were returned to me(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-10-31 23:17:58 評論於 Review speed: 6.0 | Submission success rate: 50.0 Experience sharing: If my problem was a Death Star, this article is a photon torpedo(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-08-09 08:44:17 評論於 very difficult(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2010-08-08 09:58:59 評論於 Difficult!(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us